Draper的LEAP阀门在临床前研究中显示出自发的“生长”能力-动脉网

Draper's LEAP Valve Demonstrates Spontaneous "Growth" in Preclinical Studies

PR Newswire 等信源发布 2026-03-10 20:50



可切换为仅中文







CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

March 10, 2026

2026年3月10日

/PRNewswire/ -- The preclinical feasibility of Draper's Low-force Expanding/ Adaptable Pediatric (LEAP™) Valve is described in a research paper recently published in Science Advances. The LEAP Valve is a pediatric heart valve designed to 'grow' spontaneously with infants and young children, reducing the need for related surgeries and invasive procedures..

/PRNewswire/ -- 德雷珀公司低力度扩张/适应性儿童（LEAP™）瓣膜的临床前可行性被描述在最近发表于《科学进展》的一篇研究论文中。LEAP 瓣膜是一种专为婴幼儿设计的可“自发生长”的心脏瓣膜，能够减少相关手术和侵入性操作的需求。

继续阅读

Draper's Low-force Expanding/ Adaptable Pediatric (LEAP) Valve is a pediatric heart valve that adapts to a child’s growth, the first of its kind.

德雷珀的低力扩张/适应性儿科（LEAP）瓣膜是一种适应儿童生长的儿科心脏瓣膜，属于首创。

'The initial results represent an important first step towards a growth-adaptive device that can eliminate at least one surgical replacement of current commercial implants or between one and three transcatheter procedures for balloon-expandable valves implanted in infants and young children,' said Corin Williams, a biomedical engineer at Draper who leads the development team..

“初步结果代表着向一种可适应生长的装置迈出了重要的第一步，这种装置可以消除目前商业植入物至少一次手术更换，或者消除为婴儿和幼儿植入的球囊扩张瓣膜的一到三次经导管手术。”领导开发团队的德雷珀公司的生物医学工程师科林·威廉姆斯说道。

The LEAP Valve utilizes a unique stent design that acts like a low-force spring. By building these spring structures into the stent design, the whole device can spontaneously adapt diameter in the range of 7-14 mm. The force required to keep the stent in a compressed state upon implantation was determined by studying the .

LEAP阀门采用了一种独特的支架设计，其作用类似于一个低力弹簧。通过将这些弹簧结构融入支架设计中，整个装置可以在7-14毫米的范围内自发适应直径。支架在植入时保持压缩状态所需的力是通过研究确定的。

mechanical properties of pulmonary artery tissue

肺动脉组织的机械性能

. This enables the spring to be compressed and then expand as the child grows without damaging the surrounding tissues.

这使得弹簧能够随着孩子的成长被压缩然后扩展，而不会损害周围的组织。

The feasibility tests were conducted using rapidly growing piglets as a model for pediatric patients. At implantation, the LEAP Valve was constrained to the appropriate small diameter (~8-9 mm, similar to human infants) and demonstrated good valve function. The valves were examined at one-week intervals spanning two to six weeks post-implantation, showing proportional expansion with growth and reaching 13 mm diameter (50% increase) after six weeks, or roughly the equivalent valve diameter of a four- to six-year-old child.

可行性测试使用快速生长的仔猪作为儿科患者的模型进行。在植入时，LEAP瓣膜被限制在适当的小直径（约8-9毫米，类似于人类婴儿），并显示出良好的瓣膜功能。植入后两周至六周期间，每周对瓣膜进行检查，结果显示瓣膜随生长成比例扩张，并在六周后达到13毫米直径（增加了50%），大约相当于四至六岁儿童的瓣膜直径。

。

The research paper published in

发表在

Science Advances

科学进展

describes the device design and its preclinical testing results. The paper, '

描述了设备设计及其临床前测试结果。论文，'

Design and Preclinical Feasibility of a Pediatric Heart Valve Stent that Spontaneously Adapts to Growth via a Spring Mechanism

设计和临床前可行性研究：一种通过弹簧机制自发适应生长的儿童心脏瓣膜支架

,' was co-authored by: Draper's Giselle Ventura, James S. Malloy, Ian McGinty, David W. Sutherland Jr., Baturalp Arslan, Daniel F. King, David J. Carter, and Corin Williams; Masaki Kajimoto, Lyubomyr Bohuta, Kevin A. Charette, Kyle Bilodeau, Michael A. Portman from the Seattle Children's Research Institute; Mossab Saeed, Gianna Dafflisio, Shannen B.

，由以下人员共同撰写：德雷珀的吉赛尔·文图拉、詹姆斯·S·马洛伊、伊恩·麦金太、大卫·W·萨瑟兰二世、巴图拉普·阿尔斯兰、丹尼尔·F·金、大卫·J·卡特和科林·威廉姆斯；梶本正树、柳博米尔·博胡塔、凯文·A·查雷特、凯尔·比洛多、迈克尔·A·波特曼来自西雅图儿童研究所；莫萨布·赛义德、吉安娜·达夫利西奥、香农·B。

Kizilski, Peter E. Hammer, and Sitaram M. Emani from Boston Children's Hospital; and John P. Carney of the University of Minnesota, Experimental Surgical Services Laboratory..

波士顿儿童医院的基齐尔斯基、彼得·E.哈默和西塔拉姆·M.埃马尼；以及明尼苏达大学实验外科服务实验室的约翰·P.卡尼。

This work was supported by the U.S. Army Medical Research Acquisition Activity, through the program, 'Growth-Adaptive Pediatric Heart Valves: Addressing a Critical Unmet Need for Infants and Young Children That Saves Lives and Reduces Surgeries,' under award number W81XWH2010295. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense..

这项工作得到了美国陆军医学研究采购活动的支持，通过“生长适应性儿科心脏瓣膜：满足婴儿和幼儿的关键未满足需求，挽救生命并减少手术”项目，授予编号为W81XWH2010295。意见、解释、结论和建议属于作者个人，并不一定得到国防部的认可。

In conducting research using animals, the investigators adhered to the laws of the United States and regulations of the Department of Agriculture.

在使用动物进行研究时，研究人员遵守了美国的法律和农业部的规定。

About Draper

关于德雷珀

Draper is a non-profit research, development, and manufacturing company that solves some of the nation's most important challenges. With more than 2,500 employees working in collaboration across 12 locations, Draper delivers transformative, mission-driven solutions that successfully meet our customers' requirements.

Draper是一家非营利性的研究、开发和制造公司，致力于解决国家一些最重要的挑战。Draper拥有2500多名员工，在12个地点通力合作，提供变革性、使命驱动的解决方案，成功满足客户的需求。

These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the .

这些努力集中在四个关键任务领域：战略系统、空间系统、电子系统和生物技术系统。为了将我们的遗产延续到未来，。

Draper Scholars

德雷珀学者

program engages with the next generation of innovators while

该计划在与下一代创新者互动的同时

DraperSPARX™

德雷珀SPARX™

seeks to partner with startups and small businesses that can further our mission. To learn more about Draper, visit

寻求与能够进一步推动我们使命的初创企业和小企业合作。欲了解更多关于德雷珀的信息，请访问

www.draper.com

. Follow Draper on

跟随 Draper 在